CD274 and non-small cell lung carcinoma: In NSCLC, two large phase III studies revealed the superiority of pembrolizumab over chemotherapy in prolonging survival in platinum-refractory and chemotherapy-naïve patients harboring PD-L1 expression > 1% and > 50%, respectively [8, 9].